Intravenous Administration

Mechanism

Related News

Nanoparticle Therapy Targets Lung Cancer and Muscle Wasting Simultaneously

Researchers have developed lipid nanoparticles that deliver mRNA therapeutics to simultaneously treat lung cancer and associated muscle wasting. The nanoparticles target lung tumors while preserving muscle mass, showing 2.5 times greater tumor reduction in preclinical models. This dual-action approach addresses both the primary tumor and debilitating cachexia syndrome.

FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC

The FDA approved subcutaneous amivantamab for EGFR-mutated NSCLC in December 2025 based on phase 3 PALOMA-3 trial data showing noninferior efficacy with reduced infusion reactions and 5-minute administration time. The formulation decreases infusion-related reactions from 66% to 13% and improves patient convenience and quality of life. Recent MARIPOSA trial updates show amivantamab plus lazertinib extends median overall survival by at least 12 months versus osimertinib monotherapy.